1. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
- Author
-
Yves Mentens, Jose Ferri, Godefridus J. Peters, Elisa Giovannetti, Nele Van Der Steen, Paul Germonpré, M. Ramael, Patrick Pauwels, Leticia G. Leon, David R. Gandara, Christian Rolfo, CCA - Cancer biology and immunology, Medical oncology laboratory, Medical oncology, CCA - Cancer Treatment and quality of life, and Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Cancer Research ,Lung Neoplasms ,medicine.medical_treatment ,Viral Oncogene ,medicine.disease_cause ,Targeted therapy ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Anaplastic lymphoma kinase ,Anaplastic Lymphoma Kinase ,Genetic Testing ,Molecular Targeted Therapy ,Epidermal growth factor receptor ,Neoplasm Metastasis ,Lung cancer ,Genetic testing ,biology ,medicine.diagnostic_test ,business.industry ,Middle Aged ,Proto-Oncogene Proteins c-met ,medicine.disease ,ErbB Receptors ,030104 developmental biology ,Oncology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,biology.protein ,Female ,Human medicine ,KRAS ,business - Abstract
Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity in genetic testing, more and more tumors with multiple driver mutations are identified, resulting in dilemmas for treating physicians whether and which targeted therapy to use. In this case series, we provide an overview of patients with intrinsic double mutations in oncogenic drivers and their reported response to targeted therapies, with a focus on epidermal growth factor receptor, anaplastic lymphoma kinase, cMET, and Kirsten rat sarcoma viral oncogene. We also include an unpublished case report on a patient with an epidermal growth factor receptor L858R and cMET exon 14 skipping.
- Published
- 2018
- Full Text
- View/download PDF